Skip to main content
. 2023 Apr 25;381:e074572. doi: 10.1136/bmj-2022-074572

Fig 2.

Fig 2

Event rates of post-acute sequelae in molnupiravir group (n=11 472) and no treatment group (n=217 814). Post-acute outcomes were ascertained 30 days after a first SARS-CoV-2 positive test result between 5 January 2022 and 15 January 2023 until end of follow-up. Event rates were estimated based on inverse probability weighting method. Shading represents 95% confidence intervals (CIs)